New therapies for hemophilia

Hematology (United States)

Volumn 2016, Issue 1, 2016, Pages 650-656

  Pipe, Steven W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT FACTOR VIII FC FUSION PROTEIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; F8 PROTEIN, HUMAN;

ADULT; ARTICLE; BLEEDING; CASE REPORT; CHILD; CHRONIC PAIN; CLINICAL ARTICLE; CLINICAL OUTCOME; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MALE; METRORRHAGIA; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; PRESCHOOL CHILD; RANGE OF MOTION; SCHOOL CHILD; SYNOVITIS; TREATMENT DURATION; TREATMENT REFUSAL; YOUNG ADULT; BLOOD; COMPLICATION; HEMORRHAGE;

FACTOR IX; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS;

EID: 85020240344     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2016.1.650     Document Type: Article

References (43)

1. Ljung R, Gretenkort Andersson N. The current status of prophylactic replacement therapy in children and adults with haemophilia. Br J Haematol. 2015; 169(6): 777-786.
2. Tagliaferri A, Di Perna C, Rivolta GF. Secondary prophylaxis in adolescent and adult haemophiliacs. Blood Transfus. 2008; 6(Suppl. 2): s17-s20.
3. Mazepa MA, Monahan PE, Baker JR, Riske BK, Soucie JM; US Hemophilia Treatment Center Network. Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood. 2016; 127(24): 3073-3081.
4. Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015; 125(13): 2038-2044.
5. Collins PW, Blanchette VS, Fischer K, et al.; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009; 7(3): 413-420.
6. Fischer K, Berntorp E. Targeting factor replacement therapy in severe hemophilia: which level is important? Semin Thromb Hemost. 2015; 41(8): 860-863.
7. Aledort L, Ljung R, Mann K, Pipe S. Factor VIII therapy for hemophilia A: current and future issues. Expert Rev Hematol. 2014; 7(3): 373-385.
8. Valentino LA, Negrier C, Kohla G, et al. The first recombinant FVIII produced in human cells - an update on its clinical development programme. Haemophilia. 2014; 20(Suppl. 1): 1-9.
9. Kumar R, Dunn A, Carcao M. Changing paradigm of hemophilia management: extended half-life factor concentrates and gene therapy. Semin Thromb Hemost. 2016; 42(1): 18-29.
10. Berntorp E, Andersson NG. Prophylaxis for hemophilia in the era of extended half-life factor VIII/factor IX products. Semin Thromb Hemost. 2016; 42(5): 518-525.
11. Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016; 388(10040): 187-197.
12. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood. 2013; 122(22): 3568-3574.
13. Carcao M, Srivastava A. Factor VIII/factor IX prophylaxis for severe hemophilia. Semin Hematol. 2016; 53(1): 3-9.
14. Nolan B, Mahlangu J, Perry D, et al. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A. Haemophilia. 2016; 22(1): 72-80.
15. Buckley B, Livingston T, Krishnan S, Odom T. Real-world dosing of factor VIII in hemophilia A patients. J Manag Care Spec Pharm. 2014; 20(10-a): S21.
16. Den Uijl IE, Mauser Bunschoten EP, Roosendaal G, et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia. 2011; 17(6): 849-853.
17. Ehrenforth S. N8-GP - a new long-acting factor VIII for the treatment of patients with haemophilia A. Haemophilia. 2014; 20(suppl 3): 188.
18. Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: a multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016; 141: 69-76.
19. Santagostino E, Martinowitz U, Lissitchkov T, et al.; PROLONG-9FP Investigators Study Group. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood. 2016; 127(14): 1761-1769.
20. Nolan B, Young G, Rangarajan S, et al. Analysis of bleeding rates in pediatric subjects with target joints and severe hemophilia A receiving prophylaxis with recombinant factor VIII Fc fusion protein (rFVIIIFC) in Kids A-Long. J Thromb Haemost. 2015; 13(S2): 347.
21. Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA. 2012; 308(14): 1452-1459.
22. Mahlangu J, Powell JS, Ragni MV, et al.; A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014; 123(3): 317-325.
23. Powell JS, Pasi KJ, Ragni MV, et al.; B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med. 2013; 369(24): 2313-2323.
24. Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015; 13(6): 967-977.
25. Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015; 126(9): 1078-1085.
26. Valentino LA, Mamonov V, Hellmann A, et al.; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012; 10(3): 359-367.
27. Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011; 17(1): 2-10.
28. Björkman S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia. 2010; 16(4): 597-605.
29. Borel Y. Haptens bound to self IgG induce immunologic tolerance, while when coupled to syngeneic spleen cells they induce immune suppression. Immunol Rev. 1980; 50: 71-104.
30. Zambidis ET, Scott DW. Epitope-specific tolerance induction with an engineered immunoglobulin. Proc Natl Acad Sci USA. 1996; 93(10): 5019-5024.
31. Ephrem A, Chamat S, Miquel C, et al. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood. 2008; 111(2): 715-722.
32. Lei TC, Scott DW. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood. 2005; 105(12): 4865-4870.
33. De Groot AS. Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases? Expert Rev Clin Immunol. 2013; 9(12): 1155-1157.
34. Anthony RM, Wermeling F, Ravetch JV. Novel roles for the IgG Fc glycan. Ann N Y Acad Sci. 2012; 1253: 170-180.
35. Quast I, Lünemann JD. Fc glycan-modulated immunoglobulin G effector functions. J Clin Immunol. 2014; 34(Suppl. 1): S51-S55.
36. Gupta N, Culina S, Meslier Y, et al. Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance. Sci Transl Med. 2015; 7(275): 275ra21.
37. Groomes CL, Gianferante DM, Crouch GD, Parekh DS, Scott DW, Lieuw K. Reduction of factor VIII inhibitor titers during immune tolerance induction with recombinant factor VIII-Fc fusion protein. Pediatr Blood Cancer. 2016; 63(5): 922-924.
38. Malec LM, Ragni MV, Journeycake JM, Alabek M. Immune tolerance induction using rFVIIIFc (Eloctate) [abstract]. Blood. 2015; 126(23). Abstract 3531.
39. Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016; 374(21): 2054-2064.
40. Monahan PE Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors. Hematology Am Soc Hematol Educ Program. 2015; 2015: 33-40.
41. Giangrande P. The future of hemophilia treatment: longer-acting factor concentrates versus gene therapy. Semin Thromb Hemost. 2016; 42(5): 513-517.
42. Ward P, Walsh CE. Current and future prospects for hemophilia gene therapy. Expert Rev Hematol. 2016; 9(7): 649-659.
43. Impact Education, LLC, National Hemophilia Foundation, Postgraduate Institute for Medicine. Factor VIII and IX therapeutic agents recently approved or in late phase clinical development. Available at: www.managedcarehemo.com. Accessed 20 September, 2016.